Voyageur Pharmaceuticals Ltd (VM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Voyageur Pharmaceuticals Ltd (VM) has a cash flow conversion efficiency ratio of -0.295x as of November 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-369.98K ≈ $-267.64K USD) by net assets (CA$1.25 Million ≈ $906.00K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Voyageur Pharmaceuticals Ltd market cap and net worth for the company's overall valuation and market capitalisation.
Voyageur Pharmaceuticals Ltd - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Voyageur Pharmaceuticals Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Voyageur Pharmaceuticals Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Voyageur Pharmaceuticals Ltd ranked by their cash flow conversion efficiency. Explore VM cash to earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Schlatter Industries AG
SW:STRN
|
-0.197x |
|
Ihlas Gazetecilik AS
IS:IHGZT
|
-0.003x |
|
Seojin Automotive Co.Ltd
KQ:122690
|
0.107x |
|
Synergy House Berhad
KLSE:0279
|
0.111x |
|
Nucletron Electronic Aktiengesellschaft
F:NUC
|
0.004x |
|
Rexit Bhd
KLSE:0106
|
0.034x |
|
Ikonisys SA
PA:ALIKO
|
-0.014x |
|
Naas Technology Inc ADR
NASDAQ:NAAS
|
-0.015x |
Annual Cash Flow Conversion Efficiency for Voyageur Pharmaceuticals Ltd (2011–2025)
The table below shows the annual cash flow conversion efficiency of Voyageur Pharmaceuticals Ltd from 2011 to 2025. View VM live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-11-30 | CA$1.25 Million ≈ $906.00K |
CA$-2.89 Million ≈ $-2.09 Million |
-2.310x | -243.80% |
| 2024-11-30 | CA$449.96K ≈ $325.49K |
CA$-302.29K ≈ $-218.67K |
-0.672x | +2.69% |
| 2023-11-30 | CA$1.44 Million ≈ $1.04 Million |
CA$-991.25K ≈ $-717.06K |
-0.690x | +41.17% |
| 2022-11-30 | CA$1.46 Million ≈ $1.06 Million |
CA$-1.72 Million ≈ $-1.24 Million |
-1.174x | -35.22% |
| 2021-11-30 | CA$1.91 Million ≈ $1.38 Million |
CA$-1.65 Million ≈ $-1.20 Million |
-0.868x | +2.33% |
| 2020-11-30 | CA$306.33K ≈ $221.60K |
CA$-272.19K ≈ $-196.90K |
-0.889x | -5.05% |
| 2019-11-30 | CA$754.09K ≈ $545.50K |
CA$-637.81K ≈ $-461.38K |
-0.846x | +11.07% |
| 2018-11-30 | CA$515.68K ≈ $373.04K |
CA$-490.45K ≈ $-354.79K |
-0.951x | -113.60% |
| 2017-11-30 | CA$-89.24K ≈ $-64.55K |
CA$-624.24K ≈ $-451.56K |
6.995x | +13473.35% |
| 2016-11-30 | CA$670.46K ≈ $485.00K |
CA$-35.07K ≈ $-25.37K |
-0.052x | +94.07% |
| 2015-11-30 | CA$80.07K ≈ $57.92K |
CA$-70.65K ≈ $-51.11K |
-0.882x | -204.17% |
| 2014-11-30 | CA$81.56K ≈ $59.00K |
CA$-23.66K ≈ $-17.11K |
-0.290x | +6.71% |
| 2013-11-30 | CA$176.02K ≈ $127.33K |
CA$-54.73K ≈ $-39.59K |
-0.311x | -3070.28% |
| 2012-11-30 | CA$221.34K ≈ $160.12K |
CA$2.32K ≈ $1.68K |
0.010x | +106.87% |
| 2011-11-30 | CA$185.00K ≈ $133.83K |
CA$-28.19K ≈ $-20.39K |
-0.152x | -- |
About Voyageur Pharmaceuticals Ltd
Voyageur Pharmaceuticals Ltd., together with its subsidiaries, engages in acquiring, exploring, and developing raw materials for pharmaceutical products in the United States of America, the province of British Columbia, Canada, and the state of Utah. It develops barium and iodine-based APIs. The company offers Smooth HD, Smooth X, Smooth LD, Vision HD, Vision LD, V-Gas, and other products. The co… Read more